Aduro BioTech Inc (NASDAQ:ADRO) insider Stephen T. Isaacs sold 72,051 shares of Aduro BioTech stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $8.48, for a total value of $610,992.48. Following the transaction, the insider now directly owns 231,380 shares in the company, valued at approximately $1,962,102.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Aduro BioTech Inc (ADRO) opened at $8.75 on Monday. Aduro BioTech Inc has a fifty-two week low of $5.82 and a fifty-two week high of $14.05.
Several research analysts recently issued reports on ADRO shares. BidaskClub cut Aduro BioTech from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. ValuEngine cut Aduro BioTech from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Canaccord Genuity reaffirmed a “buy” rating on shares of Aduro BioTech in a research report on Friday, March 2nd. Zacks Investment Research raised Aduro BioTech from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a research report on Tuesday, March 6th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $15.00 price target on shares of Aduro BioTech in a report on Monday, March 5th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $14.50.
COPYRIGHT VIOLATION WARNING: “Insider Selling: Aduro BioTech Inc (ADRO) Insider Sells 72,051 Shares of Stock” was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3256930/insider-selling-aduro-biotech-inc-adro-insider-sells-72051-shares-of-stock.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.